GSK (GlaxoSmithKline)GSK
Recorded

GSK (GlaxoSmithKline) ESMO 2026 Investor Briefing

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration1 hr 10 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Jeff McLaughlinVP and Interim Head of Investor Relations

Good afternoon and good morning. Thank you for joining our analyst briefing to cover data presented at the European Society for Medical Oncology in recent days. Today's discussion will be focused only on recently presented clinical data. We will not be providing any commentary on performance as we report our Q3 results tomorrow. We are joined today by Nina Mojas, our President of Global Product Strategy, Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D, and Ahmed Rabie, Senior Vice President of Global Product Strategy for Oncology. We are also joined by Eric Richards, Richard Davidson, and Claus Becker from the Oncology R&D team for the Q&A portion of this session. For the agenda, Hesham will take you through the data, and then Nina will provide some closing remarks before opening up for your questions. I will now hand over to Hesham.

Hesham AbdullahSVP and Global Head of Oncology R&D

Jeff, thank you very much, and it's a pleasure to be with everyone. Good afternoon to those in Europe, good morning to those in the U.S. And thank you very much for joining us. Of course, we are just back from Madrid. Very exciting ESMO. More than 21 abstracts, and a number of different oral presentations as well too from the GSK oncology pipeline. I am happy to take maybe the next 25-30 minutes to walk you through some of the key data from our oncology portfolio that was recently presented at ESMO in Madrid. With that, I think we could probably start off first with Ris-Rez, which is our B7-H3 ADC, of course. I think first and foremost, it's important to highlight that we actually presented some data from across our phase I-II development program.

Hesham AbdullahSVP and Global Head of Oncology R&D

This is the GSK development program, global development program, more specifically as well too. We actually had data from our phase I-II study, and specifically in small cell lung cancer. I think what's probably important to highlight is this data certainly showed consistency between the global data set that we have generated in terms of objective response rate and second line plus small cell lung cancer with a 61% response rate in the 8 mg per kg dose cohort. This is actually the dose that will be used and is being used currently in the second line phase III small cell lung cancer study across our own global development program. Then, of course, data that's been generated recently, at World Lung from our partners, Hansoh, and the ARTEMIS-008 study, where we saw an objective response rate of 58%.

Hesham AbdullahSVP and Global Head of Oncology R&D

I think probably the first key headline to take is certainly the data from our emerging global development program is very reassuring and confirms certainly the clinical activity that's being observed in the China Hansoh development program. Next slide, please. This is, of course, the data that was recently presented by Hansoh from the ARTEMIS-008 trial, looking at Ris-Rez versus topotecan in second-line small cell lung cancer. I think probably what's important to highlight and remind everyone of course, is the study was positive, demonstrating a statistically significant and clinically meaningful overall survival benefit for Ris-Rez relative to topotecan, with a median overall survival of 18.5 months versus 10.3 months on the topotecan arm. As you can probably see from the Kaplan-Meier curves, the curves separate early. That separation is maintained over time.

Hesham AbdullahSVP and Global Head of Oncology R&D

At a landmark of about 12 months, which is certainly the median duration of follow-up on the study, there were about maybe 64.5% of patients still alive on the Ris-Rez arm versus 43.3% on the topotecan arm. Next slide, please. This is a slide showing certainly a consistency of the overall survival effect across key subgroups from the ARTEMIS-008 trial. What I'd probably call your attention to is the fact that about maybe 17% of these patients that were recruited into the study did have brain metastases at study entry. What we did observe was that there was certainly a consistent treatment effect across this subgroup as well too, with a hazard ratio of 0.36 for overall survival, but generally, certainly consistent survival benefit observed across all predefined subgroups, whether it be based on age, smoking history, prior PDL1 therapy, and of course, performance status as well.

Hesham AbdullahSVP and Global Head of Oncology R&D

Next slide, please. Key secondary endpoints, of course, PFS by independent and investigator review, quite consistent, with a hazard ratio of 0.33 for the BICR-assessed PFS, 0.35 for investigator-assessed PFS, with about maybe a 4-month delta on median PFS, certainly, whether it be based on BICR or investigator assessment as well too. Next slide, please. Of course, objective response rate, disease control, and duration of response. What I'll probably call your attention to on this slide, of course, is the objective response rate that's been observed and I've noted previously, 58.3% for Ris-Rez versus 12.8 for the control arm with single-agent topotecan. I would say maybe close to a fivefold difference in the magnitude of effect on response, supported of course by the median duration of response, close to about maybe 7 months and the disease control rate as well too.

Hesham AbdullahSVP and Global Head of Oncology R&D

One point to highlight here, which I think is really important in terms of how we think about the extrapolation of data from China. What you see in this study specifically is there's a really strong internal consistency of results. If you look at the primary endpoint and the magnitude of effect that's observed on overall survival with a hazard ratio of 0.46, key secondary endpoints like PFS with a hazard ratio of 0.33, and then this fivefold difference in response rate as well too. That strong internal validity and consistency within the phase III study itself gives us certainly strong confidence in its external validity as well too, and broader application across other countries and regions. Next slide, please. Maybe just a quick summary then.

Hesham AbdullahSVP and Global Head of Oncology R&D

Again, of course, just the caveat as always of looking at cross-study comparisons and the differences that may exist between baseline characteristics across each of these studies, just taking that into account. But at least when we look at a high level, the median overall survival from the ARTEMIS-008 compared to some of the emerging data across the B7-H3 class, but also some of the existing data as well too, in second-line small cell lung cancer with immune cell engagers. No doubt the median overall survival with Ris-Rez at 18.5 months, certainly quite well-positioned in that regard. We have two phase III studies in small cell lung cancer, an ongoing phase III and second-line small cell lung cancer, which is the EMBOLD-SCLC-301 trial, which is currently recruiting.

Hesham AbdullahSVP and Global Head of Oncology R&D

Then a second study in first-line small cell lung cancer that will be initiated very shortly before the end of the year in the first-line setting as well too. Next slide. So one of the additional data sets that were actually presented as well too at ESMO was an analysis that we conducted from our own global development program looking at the incidence of ILD, given that this is certainly an event of interest across the TOPO1-based class of ADCs as well too. When we have looked at this across our certainly data set, whether it be across all solid tumors or specifically in non-small cell and small cell lung cancer, we do see a relatively low incidence of grade 3 or greater ILD events at 0.9%, so less than 1%.

Hesham AbdullahSVP and Global Head of Oncology R&D

Then, of course, in the overall at least aggregate population from our own development program, across all solid tumors, a 4% incidence of all grade events. Again, the majority of these events were, of course, mild or moderate grade 1 and 2 in nature. I think when you look at also the data that has been published from the Hansoh experience in China, whether it be with the ARTEMIS-003 or ARTEMIS-002 studies, these are phase I and II trials. We do see a relatively low incidence of grade 3 or greater ILD events as well too. Of course, ARTEMIS-008 being the exception to that with an incidence of 4% of grade 3 or greater ILD. Next slide. This was, of course, all presented on a poster at ESMO that included, of course, the ILD data for reference. Next slide, please. Then, of course, data that was presented just yesterday in an afternoon presidential symposia at ESMO.

Hesham AbdullahSVP and Global Head of Oncology R&D

I would say quite a landmark result, just given certainly how challenging this disease is, osteosarcoma, quite poorly prognostic. We have not seen any advances in standard of care over the past 50 years, as one leading sarcoma expert had told us. I think that is really important to highlight and emphasize as well, too. Next slide, please. So this basically was a study looking at osteosarcoma patients in an advanced metastatic second-line disease setting. So patients had received certainly greater than 1 to 2 prior lines, specifically at least 2 prior lines. Patients were randomized 2 to 1, either to receive Ris-Rez or certainly standard of care gemcitabine docetaxel chemotherapy. Then the primary endpoint of the study was PFS by blinded independent review.

Hesham AbdullahSVP and Global Head of Oncology R&D

Key secondary endpoints included overall survival and PFS and objective response rate. Of course, given the sample size of the study, which is 122 patients, the study is not powered for overall survival. Next slide, please. Key baseline demographics. When we look at the median age of these patients, it is ranging between 21 to 22 months, and I think that is really important to highlight. Just given the patients that are typically impacted by osteosarcoma, we have about maybe a quarter of patients that were actually adolescents between 12 to 18 years of age. So certainly, at least the incidence tends to also occur in younger patients, as evidenced by the data. I think one thing to probably also highlight is this is a patient population that no doubt had a relatively high disease burden, as evidenced by the fact that the majority of these patients had pulmonary metastases.

Hesham AbdullahSVP and Global Head of Oncology R&D

And of course, is also heavily pretreated. The majority of these patients had received prior chemotherapy and targeted therapy as well, too. Next slide, please. The primary endpoint, BICR-assessed PFS, was met, demonstrating a statistically significant and clinically meaningful improvement in PFS with close to a fourfold improvement, 5.5 months versus 1.4 months in terms of the medians. Again, you see the curves separate relatively early and certainly stay separated until that 6-month landmark. I think it's important to highlight, of course, the median duration to follow-up at this point in time is about maybe 7.1 months. Next slide, please. Tumor response assessment by BICR as well, too. The objective response rate is 15% on the Ris-Rez arm and 2% on the gemcitabine docetaxel arm. Now, one thing to bear in mind, and especially with this type of tumor, just given the location of the tumor itself in the bone.

Hesham AbdullahSVP and Global Head of Oncology R&D

Oftentimes, one of the challenges is really getting enough exposure to be able to penetrate these lesions, especially given the thickness of the extracellular matrix that exists around the tumor and the capsule within the bone itself as well, too. So I would say probably objective response rate is not necessarily the most meaningful way to assess the activity of the drug, but rather, of course, a disease control rate may be a better proxy along with PFS. And here, as you can probably see, the disease control rate is at 76% on the Ris-Rez arm versus 33% on the control arm. I think one other point to highlight, the dose that was used of Ris-Rez in this study was 12 mgs per kg.

Hesham AbdullahSVP and Global Head of Oncology R&D

I mentioned and alluded to the fact that higher exposure may be needed here, given the need to be able to better penetrate, of course, the tumor, especially given its location and its site as well, too. Next slide, please. Overall survival data, currently immature. It's about, I would say, 16%-17% mature at this point in time, with about 10 events having occurred in each arm. The study did allow for crossover, so we did note that 17 patients in the control arm have already crossed over to Ris-Rez treatment following progression on gemcitabine. And despite that, we're still seeing certainly a very encouraging trend at this point in time on overall survival with a hazard ratio of 0.51. And again, awaiting further follow-up, just given the relative immaturity of the overall survival at this point in time. Next, please. Safety profile, I would say certainly as expected, given the dose that was used here, but also the typical Topo 1-based payload assessed toxicities or related toxicities all predominantly relating to myelosuppression, including, of course, neutropenia and, of course, thrombocytopenia, being the key ones.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day